Figure 4.

GAPDH overexpression induces Bcl-xL upregulation in several cell lines through Akt pathway activation. (a–c) Expression of Bcl-xL was assessed by immunoblots of Mock and GAPDH-V5-overexpressing HeLa (a), LS174 (b) or K562 (c) cell lines. (d and e) Mock or GAPDH-V5 HeLa cells were treated for 48 h with 1 μM Akti (d) or 0.5 μg/ml GAPDH inhibitor (KA, e), and analyzed as described in panel a. (f and g) Mock or GAPDH-V5 HeLa cells were transiently transfected 48 h with 50 nM siRNA targeting Akt1/2 (f) or FoxO1A (g), and analyzed as described in panel a. The immunoblots are representative of 3–5 independent experiments. Erk2 was used as a loading control. The Bcl-xL/Erk2 ratios were quantified and normalized to Mock cells